Epidemiology of Community Acquired Pneumonia in North Israel

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2006 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00390819
First received: October 19, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
  Purpose

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.


Condition
Community Acquired Pneumonia

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Epidemiology of Community Acquired Pneumonia in North Israel

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Estimated Enrollment: 100
Study Start Date: November 2006
Detailed Description:

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality.

CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential.

Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment.

Material & Methods:

We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant.

In addition to demographic and clinical data, following tests will be performed:

  1. Blood cultures
  2. Sputum
  3. PCR - throat culture to the following pathogens:

    • Mycoplasma pneumoniae
    • Chlamydia pneumoniae
    • Legionella
    • Adenovirus
    • Influenza A
    • Influenza B
    • RSV
    • Metapneumovirus
    • Parainfluenza
    • Pneumococcal antigen in urine
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Community acquired pneumonia
  • Hospitalization

Exclusion Criteria:

  • Immunocompromised patients
  • Patients under chemotherapy treatment
  • Patients under steroids treament
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00390819

Contacts
Contact: Fahmi Shibli, M.D. 972-4-6494000 ext 4347 fahmi_shibli@yahoo.ie

Locations
Israel
Ha'Emek Medical Center Not yet recruiting
Afula, Israel, 18101
Contact: Fahmi Shibli, M.D.    972-4-6494000 ext 4347    fahmi_shibli@yahoo.ie   
Sub-Investigator: Raul Raz, M.D.         
Sub-Investigator: Raul Colodner, PhD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: Fahmi Shibli, M.D. Ha'Emek Medical Center, Afula, Israel
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00390819     History of Changes
Other Study ID Numbers: 131074
Study First Received: October 19, 2006
Last Updated: October 19, 2006
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
Community acquired pneumonia

Additional relevant MeSH terms:
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on July 29, 2014